SG11201600337PA - SELF-EMULSIFYING COMPOSITION OF ω-3 FATTY ACID - Google Patents
SELF-EMULSIFYING COMPOSITION OF ω-3 FATTY ACIDInfo
- Publication number
- SG11201600337PA SG11201600337PA SG11201600337PA SG11201600337PA SG11201600337PA SG 11201600337P A SG11201600337P A SG 11201600337PA SG 11201600337P A SG11201600337P A SG 11201600337PA SG 11201600337P A SG11201600337P A SG 11201600337PA SG 11201600337P A SG11201600337P A SG 11201600337PA
- Authority
- SG
- Singapore
- Prior art keywords
- self
- fatty acid
- emulsifying composition
- emulsifying
- composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Dispersion Chemistry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Emergency Medicine (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013149662 | 2013-07-18 | ||
| PCT/JP2014/069114 WO2015008848A1 (ja) | 2013-07-18 | 2014-07-17 | ω３脂肪酸の自己乳化組成物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201600337PA true SG11201600337PA (en) | 2016-02-26 |
Family
ID=52346290
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201600337PA SG11201600337PA (en) | 2013-07-18 | 2014-07-17 | SELF-EMULSIFYING COMPOSITION OF ω-3 FATTY ACID |
| SG10201800243XA SG10201800243XA (en) | 2013-07-18 | 2014-07-17 | SELF-EMULSIFYING COMPOSITION OF ω-3 FATTY ACID |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201800243XA SG10201800243XA (en) | 2013-07-18 | 2014-07-17 | SELF-EMULSIFYING COMPOSITION OF ω-3 FATTY ACID |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20160158184A1 (de) |
| EP (2) | EP3023099B1 (de) |
| JP (4) | JPWO2015008848A1 (de) |
| KR (1) | KR102275447B1 (de) |
| CN (4) | CN110840874A (de) |
| CA (1) | CA2918330C (de) |
| ES (1) | ES2841344T3 (de) |
| HK (1) | HK1222551A1 (de) |
| MY (1) | MY187003A (de) |
| PH (1) | PH12016500100A1 (de) |
| SG (2) | SG11201600337PA (de) |
| WO (1) | WO2015008848A1 (de) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3187182B1 (de) | 2008-09-02 | 2021-03-03 | Amarin Pharmaceuticals Ireland Limited | Pharmazeutische zusammensetzungen mit eicosapentaensäure und nikotinsäure und verfahren zur verwendung davon |
| BRPI1011876B1 (pt) | 2009-04-29 | 2020-03-31 | Amarin Pharma, Inc. | Composições farmacêuticas estáveis compreendendo etilácido eicosapentaenoico (etil-epa) e uso das mesmas para tratar ou prevenir uma doença relacionada ao cardiovascular |
| EP2424521A4 (de) | 2009-04-29 | 2015-03-04 | Amarin Pharmaceuticals Ie Ltd | Pharmazeutische zusammensetzungen mit epa und einem kardiovaskulären mittel sowie verwendungsverfahren dafür |
| DK2443246T3 (en) | 2009-06-15 | 2018-03-26 | Amarin Pharmaceuticals Ie Ltd | COMPOSITIONS AND METHODS FOR REDUCING TRIGLYCERIDES WITHOUT INCREASING LDL-C LEVELS IN AN INDIVIDUAL WITH CURRENT STATE THERAPY |
| RU2012116079A (ru) | 2009-09-23 | 2013-10-27 | АМАРИН КОРПОРЕЙШН ПиЭлСи | Фармацевтическая композиция, включающая омега-3 жирную кислоту и гидроксипроизводное статина и способы ее применения |
| US11712429B2 (en) | 2010-11-29 | 2023-08-01 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
| NZ727980A (en) | 2010-11-29 | 2018-08-31 | Amarin Pharmaceuticals Ie Ltd | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
| US20130131170A1 (en) | 2011-11-07 | 2013-05-23 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
| US11291643B2 (en) | 2011-11-07 | 2022-04-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
| AU2013207368A1 (en) | 2012-01-06 | 2014-07-24 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering levels of high-sensitivity (hs-CRP) in a subject |
| EP4342546A3 (de) | 2012-06-29 | 2024-05-22 | Amarin Pharmaceuticals Ireland Limited | Verfahren zur verringerung des risikos von herz-kreislauf-ereignissen bei einem patienten in einer statintherapie |
| WO2014074552A2 (en) | 2012-11-06 | 2014-05-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy |
| US20140187633A1 (en) | 2012-12-31 | 2014-07-03 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis |
| US9452151B2 (en) | 2013-02-06 | 2016-09-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing apolipoprotein C-III |
| US9624492B2 (en) | 2013-02-13 | 2017-04-18 | Amarin Pharmaceuticals Ireland Limited | Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof |
| US20140271841A1 (en) | 2013-03-15 | 2014-09-18 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin |
| US10966968B2 (en) | 2013-06-06 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof |
| US20150065572A1 (en) | 2013-09-04 | 2015-03-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing prostate cancer |
| US9585859B2 (en) | 2013-10-10 | 2017-03-07 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
| US10561631B2 (en) | 2014-06-11 | 2020-02-18 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing RLP-C |
| US10172818B2 (en) | 2014-06-16 | 2019-01-08 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
| RU2709612C2 (ru) | 2015-01-21 | 2019-12-19 | Мотида Фармасьютикал Ко., Лтд. | САМОЭМУЛЬГИРУЮЩАЯСЯ КОМПОЗИЦИЯ ω3 ЖИРНОЙ КИСЛОТЫ |
| JP6722118B2 (ja) * | 2015-01-21 | 2020-07-15 | 持田製薬株式会社 | ω３脂肪酸の自己乳化組成物 |
| US10406130B2 (en) | 2016-03-15 | 2019-09-10 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
| WO2018054265A1 (zh) * | 2016-09-20 | 2018-03-29 | 张碧婷 | 亲水性脂类组合物的包装组合物，其制备及调配方法和应用 |
| TW201900160A (zh) | 2017-05-19 | 2019-01-01 | 愛爾蘭商艾瑪琳製藥愛爾蘭有限公司 | 用於降低腎功能下降之個體中的三酸甘油酯之組合物及方法 |
| US11058661B2 (en) | 2018-03-02 | 2021-07-13 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L |
| KR20210110890A (ko) | 2018-09-24 | 2021-09-09 | 애머린 파마슈티칼스 아일랜드 리미티드 | 대상체에서 심혈관 사건의 위험도를 감소시키는 방법 |
| WO2022225896A1 (en) | 2021-04-21 | 2022-10-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of heart failure |
| CN116407543A (zh) * | 2021-12-29 | 2023-07-11 | 中国科学院上海药物研究所 | Epa-ee纳米脂质组合物、及其制剂、制备方法和应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0513082A (pt) | 2004-08-06 | 2008-04-22 | Transform Pharmaceuticals Inc | formulações de fenofibrato e métodos de tratamento relacionados |
| NZ595204A (en) * | 2009-03-09 | 2014-11-28 | Pronova Biopharma Norge As | Compositions comprising a fatty acid oil mixture and a surfactant, and methods and uses thereof |
| CA2762939C (en) * | 2009-05-22 | 2017-07-18 | Mochida Phamaceutical Co., Ltd. | Self-emulsifying composition of .omega.3 fatty acid |
| JP5421674B2 (ja) | 2009-07-01 | 2014-02-19 | 株式会社ファンケル | ソフトカプセル用乳化組成物及びソフトカプセル剤 |
| JP5951489B2 (ja) * | 2009-10-16 | 2016-07-13 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ | 組成物 |
| JP5820256B2 (ja) | 2011-02-10 | 2015-11-24 | 株式会社ファンケル | 自己乳化製剤 |
-
2014
- 2014-07-17 CN CN201911271882.4A patent/CN110840874A/zh active Pending
- 2014-07-17 CA CA2918330A patent/CA2918330C/en active Active
- 2014-07-17 SG SG11201600337PA patent/SG11201600337PA/en unknown
- 2014-07-17 CN CN201480040469.6A patent/CN105530927A/zh active Pending
- 2014-07-17 ES ES14826603T patent/ES2841344T3/es active Active
- 2014-07-17 CN CN202010690422.1A patent/CN111939125A/zh active Pending
- 2014-07-17 WO PCT/JP2014/069114 patent/WO2015008848A1/ja active Application Filing
- 2014-07-17 MY MYPI2016700151A patent/MY187003A/en unknown
- 2014-07-17 KR KR1020167001712A patent/KR102275447B1/ko active IP Right Grant
- 2014-07-17 CN CN202010690704.1A patent/CN111888343A/zh active Pending
- 2014-07-17 JP JP2015527342A patent/JPWO2015008848A1/ja active Pending
- 2014-07-17 SG SG10201800243XA patent/SG10201800243XA/en unknown
- 2014-07-17 US US14/905,652 patent/US20160158184A1/en not_active Abandoned
- 2014-07-17 EP EP14826603.4A patent/EP3023099B1/de active Active
- 2014-07-17 EP EP20190189.9A patent/EP3763364A1/de active Pending
-
2016
- 2016-01-15 PH PH12016500100A patent/PH12016500100A1/en unknown
- 2016-09-09 HK HK16110704.8A patent/HK1222551A1/zh unknown
-
2019
- 2019-08-08 JP JP2019146152A patent/JP2020011958A/ja active Pending
-
2021
- 2021-01-06 US US17/142,558 patent/US20210128510A1/en active Pending
-
2022
- 2022-02-01 JP JP2022013981A patent/JP2022062147A/ja active Pending
-
2023
- 2023-12-04 JP JP2023204610A patent/JP2024028839A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MY187003A (en) | 2021-08-26 |
| JP2022062147A (ja) | 2022-04-19 |
| PH12016500100B1 (en) | 2016-04-18 |
| JP2024028839A (ja) | 2024-03-05 |
| HK1222551A1 (zh) | 2017-07-07 |
| CA2918330C (en) | 2022-08-30 |
| US20160158184A1 (en) | 2016-06-09 |
| CN111939125A (zh) | 2020-11-17 |
| KR20160032120A (ko) | 2016-03-23 |
| CN105530927A (zh) | 2016-04-27 |
| CN111888343A (zh) | 2020-11-06 |
| EP3763364A1 (de) | 2021-01-13 |
| ES2841344T3 (es) | 2021-07-08 |
| EP3023099A1 (de) | 2016-05-25 |
| JPWO2015008848A1 (ja) | 2017-03-02 |
| WO2015008848A1 (ja) | 2015-01-22 |
| JP2020011958A (ja) | 2020-01-23 |
| EP3023099A4 (de) | 2017-01-04 |
| PH12016500100A1 (en) | 2016-04-18 |
| KR102275447B1 (ko) | 2021-07-08 |
| US20210128510A1 (en) | 2021-05-06 |
| CN110840874A (zh) | 2020-02-28 |
| SG10201800243XA (en) | 2018-02-27 |
| CA2918330A1 (en) | 2015-01-22 |
| EP3023099B1 (de) | 2020-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201600337PA (en) | SELF-EMULSIFYING COMPOSITION OF ω-3 FATTY ACID | |
| HK1243324A1 (zh) | ω3脂肪酸的自乳化組合物 | |
| EP3735963C0 (de) | Selbstemulgierende zusammensetzung von omega-3-fettsäure | |
| IL249821A0 (en) | Preparations of omega 3 fatty acid esters | |
| IL269227B (en) | Solid forms of treprostinil | |
| EP2861227A4 (de) | Omega-3 pentaensäurezusammensetzungen und verfahren zur verwendung | |
| HK1206248A1 (en) | Compositions of statins and omega-3 fatty acids -3 | |
| EP3248599A4 (de) | Selbstemulgierende omega-3-fettsäurezusammensetzung | |
| EP3056090A4 (de) | Öl-/fett-zusammensetzung mit mehrfach ungesättigten fettsäuren | |
| SI2984490T1 (sl) | Metode proizvodnje derivatov omega hidroksilirane maščobne kisline | |
| EP2961729A4 (de) | Herstellung von biopolyolestern für schmiermittelanwendung | |
| PL2997117T3 (pl) | Zastosowanie estru | |
| EP2827868A4 (de) | Pharmazeutische zusammensetzungen mit fettsäureestern | |
| EP3069615A4 (de) | Fett mit mehrfach ungesättigten fettsäuren | |
| PL2996484T3 (pl) | Zastosowanie kwasu tłuszczowego z oleju talowego | |
| IL279291A (en) | Morphic forms of hexadecyloxypropyl-phosphonate esters | |
| SI2860211T1 (sl) | Sestavki estra fosforne kisline z zmanjšano higroskopičnostjo | |
| EP2849571A4 (de) | Verwendung von verseifter tallölfettsäure | |
| EP2968246A4 (de) | Omega-3-pentaensäure-zusammensetzungen und verfahren zur verwendung | |
| EP2929041A4 (de) | Omega-3-pentaensäure-zusammensetzungen und verfahren zur verwendung | |
| IL245588A0 (en) | Solid compositions of triglycerides and their use | |
| EP2845585A4 (de) | Trehalose-fettsäure-ester-zusammensetzung | |
| HRP20182110T1 (hr) | Sastav spojeva tiakumicina | |
| EP2964772A4 (de) | Herstellung von omega-3-fettsäuren aus pythium-spezies | |
| SG10202103821WA (en) | SELF-EMULSIFYING COMPOSITION OF ω-3 FATTY ACID |